Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial

BACKGROUND: Extended-release naltrexone (XR-NTX), an opioid antagonist, and sublingual buprenorphine-naloxone (BUP-NX), a partial opioid agonist, are pharmacologically and conceptually distinct interventions to prevent opioid relapse. We aimed to estimate the difference in opioid relapse-free surviv...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Lancet
Päätekijät: Lee, Joshua D, Nunes, Edward V, Novo, Patricia, Bachrach, Ken, Bailey, Genie L, Bhatt, Snehal, Farkas, Sarah, Fishman, Marc, Gauthier, Phoebe, Hodgkins, Candace C, King, Jacquie, Lindblad, Robert, Liu, David, Matthews, Abigail G, May, Jeanine, Peavy, K Michelle, Ross, Stephen, Salazar, Dagmar, Schkolnik, Paul, Shmueli-Blumberg, Dikla, Stablein, Don, Subramaniam, Geetha, Rotrosen, John
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5806119/
https://ncbi.nlm.nih.gov/pubmed/29150198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(17)32812-X
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia